Arcus Biosciences, Inc. (RCUS)
| Market Cap | 2.57B +17.1% |
| Revenue (ttm) | 117.00M -55.3% |
| Net Income | -460.00M |
| EPS | -3.86 |
| Shares Out | 143.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,018,051 |
| Open | 18.23 |
| Previous Close | 18.19 |
| Day's Range | 17.76 - 18.49 |
| 52-Week Range | 17.43 - 31.74 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 41.00 (+129.69%) |
| Earnings Date | Nov 4, 2026 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in... [Read more]
Financial Performance
In 2025, Arcus Biosciences's revenue was $247.00 million, a decrease of -4.26% compared to the previous year's $258.00 million. Losses were -$353.00 million, 24.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 129.69% from the latest price.
News
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the tre...
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for t...
Arcus Biosciences 14.3M share Spot Secondary priced at $17.50
The deal range was $17.50-$18.50. Jefferies, Leerink and TD Cowen acted as joint book running managers for the offering.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatmen...
Arcus Biosciences $250M Spot Secondary; price range $17.50-$18.50
Jefferies, Leerink and TD Cowen are acting as joint book running managers for the offering.
Arcus Biosciences announces common stock offering, no amount given
Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. Jefferies,…
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the...
Arcus Biosciences falls -8.3%
Arcus Biosciences (RCUS) is down -8.3%, or -$1.98 to $21.77.
Arcus Biosciences price target raised to $41 from $40 at Truist
Truist analyst Supawat Thongthip raised the firm’s price target on Arcus Biosciences (RCUS) to $41 from $40 and keeps a Hold rating on the shares. The company had disclosed updated…
Arcus Biosciences price target raised to $50 from $45 at Citi
Citi raised the firm’s price target on Arcus Biosciences (RCUS) to $50 from $45 and keeps a Buy rating on the shares.
Arcus could rally 30%-50% on casdatifan data, says Mizuho
Mizuho analyst Salim Syed believes the data this morning from Arcus Biosciences (RCUS) positions casdatifan as an “all-line backbone therapy” in clear cell renal cell carcinoma. The shares currently p...
Arcus Biosciences presents data from ARC-20 platform study
Arcus Biosciences (RCUS) announced new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2alpha inhibito...
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for t...
Arcus Biosciences Transcript: Investor Day 2026
Casdatifan showed promising disease-control and survival signals across RCC lines, with durable HIF-2 inhibition and a TKI-sparing frontline strategy. Trials target estimated $2B second-line and $4B+ frontline opportunities.
Arcus Biosciences Slides: FY 2026
Arcus Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 20, 2026.
Arcus Biosciences Press release: FY 2026
Arcus Biosciences issued a press release on October 20, 2026, disclosing material business information to investors.
Arcus Biosciences management to hold a virtual meeting
Management discusses new data for Casdatifan as a treatment for Kidney Cancer across multiple lines of therapy in a virtual meeting to be held on October 20 at 8:30 am.
Arcus Biosciences initiated with an Outperform at William Blair
William Blair initiated coverage of Arcus Biosciences (RCUS) with an Outperform rating. Arcus is a clinical-stage small-molecule company whose lead asset, casdatifan, is a next-generation HIF-2alpha i...
Arcus Biosciences initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Arcus Biosciences (RCUS) with an Overweight rating and $41 price target The firm says its buy thesis centers on casdatifan, the company’s once-daily oral HIF-2N1 inhibit...
Arcus Biosciences to host investor event on casdatifan data
Arcus Biosciences (RCUS) will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will…
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for t...
Arcus Biosciences initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Arcus Biosciences (RCUS) with a Buy rating and no price target The company’s casdatifan could become the preferred HIF-2alphai in renal cell carcinoma given its…
Arcus Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Casdatifan is positioned as a transformative therapy in renal cell carcinoma, with pivotal data from ARC-20 and upcoming phase III trials aiming to demonstrate superiority across all lines of therapy. Commercial plans target multi-billion dollar opportunities, with key data and milestones expected from October 2024 through 2028.
Arcus Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Casdatifan is positioned for broad use in kidney cancer, with upcoming data expected to show strong efficacy and survival benefits across multiple treatment lines. The program is differentiated by robust performance in real-world populations and strategic combinations, supporting significant commercial potential.
Arcus Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant data updates for casdatifan in renal cell carcinoma are expected in October, covering late-line, second-line, and frontline settings. Pivotal studies are progressing well, with first data readouts anticipated in 2028 and a strong focus on commercial expansion and AI-driven drug discovery.